CHARLES RIVER LABORATORIES (CRL)
US1598641074 - Common Stock
Overall CRL gets a fundamental rating of 5 out of 10. We evaluated CRL against 59 industry peers in the Life Sciences Tools & Services industry. While CRL has a great profitability rating, there are quite some concerns on its financial health. CRL is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CRL was profitable.
In the past year CRL had a positive cash flow from operations.
CRL had positive earnings in each of the past 5 years.
In the past 5 years CRL always reported a positive cash flow from operatings.
1.2 Ratios
CRL has a Return On Assets of 5.79%. This is amongst the best in the industry. CRL outperforms 81.36% of its industry peers.
With an excellent Return On Equity value of 13.20%, CRL belongs to the best of the industry, outperforming 88.14% of the companies in the same industry.
CRL's Return On Invested Capital of 7.40% is amongst the best of the industry. CRL outperforms 81.36% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CRL is in line with the industry average of 9.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.79% | ||
| ROE | 13.2% | ||
| ROIC | 7.4% |
ROA(3y)5.92%
ROA(5y)5.95%
ROE(3y)14.99%
ROE(5y)15.52%
ROIC(3y)8.07%
ROIC(5y)7.97%
1.3 Margins
CRL has a better Profit Margin (11.49%) than 79.66% of its industry peers.
In the last couple of years the Profit Margin of CRL has grown nicely.
CRL's Operating Margin of 15.82% is fine compared to the rest of the industry. CRL outperforms 79.66% of its industry peers.
In the last couple of years the Operating Margin of CRL has remained more or less at the same level.
CRL has a Gross Margin of 36.89%. This is in the lower half of the industry: CRL underperforms 64.41% of its industry peers.
CRL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.82% | ||
| PM (TTM) | 11.49% | ||
| GM | 36.89% |
OM growth 3Y0.93%
OM growth 5Y0.35%
PM growth 3Y-2.65%
PM growth 5Y2.84%
GM growth 3Y0.29%
GM growth 5Y-0.02%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CRL is destroying value.
CRL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CRL has been increased compared to 5 years ago.
The debt/assets ratio for CRL has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.73 indicates that CRL is not a great score, but indicates only limited risk for bankruptcy at the moment.
CRL has a Altman-Z score of 2.73. This is comparable to the rest of the industry: CRL outperforms 55.93% of its industry peers.
CRL has a debt to FCF ratio of 7.26. This is a slightly negative value and a sign of low solvency as CRL would need 7.26 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 7.26, CRL is in the better half of the industry, outperforming 66.10% of the companies in the same industry.
CRL has a Debt/Equity ratio of 0.74. This is a neutral value indicating CRL is somewhat dependend on debt financing.
The Debt to Equity ratio of CRL (0.74) is worse than 72.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | 7.26 | ||
| Altman-Z | 2.73 |
ROIC/WACC0.63
WACC11.78%
2.3 Liquidity
A Current Ratio of 1.52 indicates that CRL should not have too much problems paying its short term obligations.
CRL has a worse Current ratio (1.52) than 84.75% of its industry peers.
A Quick Ratio of 1.16 indicates that CRL should not have too much problems paying its short term obligations.
The Quick ratio of CRL (1.16) is worse than 84.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.52 | ||
| Quick Ratio | 1.16 |
3. Growth
3.1 Past
The earnings per share for CRL have decreased by -4.31% in the last year.
The Earnings Per Share has been growing by 12.09% on average over the past years. This is quite good.
The Revenue has been growing slightly by 3.86% in the past year.
Measured over the past years, CRL shows a quite strong growth in Revenue. The Revenue has been growing by 12.75% on average per year.
EPS 1Y (TTM)-4.31%
EPS 3Y9.37%
EPS 5Y12.09%
EPS growth Q2Q-17.45%
Revenue 1Y (TTM)3.86%
Revenue growth 3Y12.2%
Revenue growth 5Y12.75%
Revenue growth Q2Q-7.85%
3.2 Future
Based on estimates for the next years, CRL will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.63% on average per year.
The Revenue is expected to grow by 7.01% on average over the next years.
EPS Next Y4.53%
EPS Next 2Y8.57%
EPS Next 3Y9.32%
EPS Next 5Y14.63%
Revenue Next Year2.85%
Revenue Next 2Y5.08%
Revenue Next 3Y5.91%
Revenue Next 5Y7.01%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 22.55, CRL is valued on the expensive side.
Based on the Price/Earnings ratio, CRL is valued cheaply inside the industry as 94.92% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 25.20. CRL is around the same levels.
CRL is valuated rather expensively with a Price/Forward Earnings ratio of 21.57.
CRL's Price/Forward Earnings ratio is rather cheap when compared to the industry. CRL is cheaper than 91.53% of the companies in the same industry.
CRL is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.60, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.55 | ||
| Fwd PE | 21.57 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CRL is valued cheaply inside the industry as 94.92% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CRL indicates a somewhat cheap valuation: CRL is cheaper than 74.58% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 33.85 | ||
| EV/EBITDA | 14.84 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of CRL may justify a higher PE ratio.
PEG (NY)4.98
PEG (5Y)1.87
EPS Next 2Y8.57%
EPS Next 3Y9.32%
5. Dividend
5.1 Amount
No dividends for CRL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CHARLES RIVER LABORATORIES
NYSE:CRL (4/23/2024, 7:04:00 PM)
After market: 240.13 0 (0%)240.13
+7.57 (+3.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.37B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.55 | ||
| Fwd PE | 21.57 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)4.98
PEG (5Y)1.87
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.79% | ||
| ROE | 13.2% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 15.82% | ||
| PM (TTM) | 11.49% | ||
| GM | 36.89% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.74 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.52 | ||
| Quick Ratio | 1.16 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-4.31%
EPS 3Y9.37%
EPS 5Y
EPS growth Q2Q
EPS Next Y4.53%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)3.86%
Revenue growth 3Y12.2%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y